2019³â ´ëÇÑ°ñ´ë»çÇÐȸ ´ë±¸°æºÏÁöȸ Á¦4Â÷ Áý´ãȸ : 2019-07-02±³À°ÀÏÀÚ : 2019-07-02
±³À°Àå¼Ò : °è¸íÀÇ´ë ¼¼¹Ì³ª½Ç
±³À°ÁÖÁ¦ :
2019³â ´ëÇÑ°ñ´ë»çÇÐȸ ´ë±¸°æºÏÁöȸ Á¦4Â÷ Áý´ãȸÁÖÃÖ±â°ü : ´ëÇÑ°ñ´ë»çÇÐȸ
´ã´çÀÚ : ÇÐȸ»ç¹«±¹
¿¬¶ôó : 02-3473-2230
À̸ÞÀÏ :
bone90@empal.com ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, Á¤½Å°Ç°ÀÇÇаú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ÈäºÎ¿Ü°ú, ¼ºÇü¿Ü°ú, ¾È°ú, À̺ñÀÎÈÄ°ú, ÇǺΰú, ºñ´¢ÀÇÇаú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, ÀçÈ°ÀÇÇаú, °áÇÙ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, »ê¾÷ÀÇÇаú, ÇÙÀÇÇаú, ÀÀ±ÞÀÇÇаúÀÇ»çÇÐ, ¹ýÀÇÇÐ, ¿¹¹æÀÇÇÐ, ÇغÎÇÐ, »ý¸®ÇÐ, »ýÈÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ±â»ýÃæÇÐ, ¾à¸®ÇÐ,
Âü¼®¿¹»óÀοø : 60¸í
Èñ¸ÁÆòÁ¡ : 2Á¡
Áö¿ª :
´ë±¸±¤¿ª½Ã±³À°½Ã°£ : 2 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 07-02 ´ë°´ç 18:20~18:25 µî·Ï ()
±âŸ 07-02 ´ë°´ç 18:25~18:30 °³È¸»ç ()
±³À°½Ã°£ 07-02 ´ë°´ç 18:30~18:55 °ñÇü¼º Á¦Á¦ Teriparatide: Anabolic agents, what is beyond osteoporosis? Á¶´ëö(°æºÏÀÇ´ë ½Å°æ¿Ü°ú)
±³À°½Ã°£ 07-02 ´ë°´ç 18:55~19:20 °ñÈí¼ö ¾ïÁ¦Á¦ Denosumab: mechanism of action and clinical outcome ±è¹Ì°æ(°è¸íÀÇ´ë ³»ºÐºñ³»°ú)
Åä·Ð 07-02 ´ë°´ç 19:20~19:40 Q & A and Discussion ()
±³À°½Ã°£ 07-02 ´ë°´ç 19:40~20:10 CASE 1 Severe osteoporosis µ¿¹ÝÇÑ Ã´ÃßÁúȯ Áõ·Ê ÀüÀÍÂù(¿µ³²ÀÇ´ë ½Å°æ¿Ü°ú)
±³À°½Ã°£ 07-02 ´ë°´ç 20:10~20:40 CASE 2 Secondary osteoporosis Áõ·Ê Á¶³Èñ(°è¸íÀÇ´ë ³»ºÐºñ³»°ú)
Åä·Ð 07-02 ´ë°´ç 20:40~20:50 Q & A and Discussion ()